NDC product
NALOXONE HCI
NDC 51662-1242 · HF Acquisition Co. LLC, DBA Health First
Key facts
| Product NDC | 51662-1242 |
|---|---|
| Proprietary name | NALOXONE HCI |
| Nonproprietary name | NALOXONE HCI |
| Substances | NALOXONE HYDROCHLORIDE |
| Dosage form | INJECTION, SOLUTION |
| Route | INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS |
| Labeler | HF Acquisition Co. LLC, DBA Health First |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA070256 |
| Pharmacologic classes | Opioid Antagonist [EPC], Opioid Antagonists [MoA] |
| Marketing start | Aug 18, 2018 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: